Accelerating Medical Treatments for Serious Mental Illness
Apr 18, 2026
Apr 18, 2026
Unpublished Executive Order
This executive order was recently signed and has not yet been published in the Federal Register. This page will be updated once the official text has been published.Summary
Aims to speed up research and approval for psychedelic drugs to treat serious mental illnesses like depression, especially for veterans.
What problem does this solve?
Many Americans, especially veterans, suffer from serious mental illness, and current treatments do not always work. This order speeds up the process for researching and approving psychedelic drugs that show promise in treating these conditions.
Who does this affect?
- People with serious mental illness
- Veterans
- Medical researchers and drug companies
What does this order do?
Prioritizes review of psychedelic drugs
Directs the Food and Drug Administration (FDA) to give priority review vouchers to certain psychedelic drugs that have received a Breakthrough Therapy designation.
Allows access through 'Right to Try'
Requires the FDA and Drug Enforcement Administration (DEA) to create a way for eligible patients to access psychedelic drugs, including ibogaine, under the Right to Try Act.
Reference
Text:
Section:
Sec. 3
Header:
Department of Health and Human Services Funding for Federal-State Collaboration
Funds state-level research programs
Allocates at least $50 million from the Department of Health and Human Services to support state governments that are developing programs for psychedelic drug treatments.
Reference
Text:
Section:
Sec. 4
Header:
Department of Health and Human Services and FDA Collaboration with the Department of Veterans Affairs and the Private Sector
Promotes data sharing between agencies
Orders the Departments of Health and Human Services, Veterans Affairs, and the FDA to work together and with private companies to share data from clinical trials on psychedelic drugs.
Speeds up drug rescheduling
Directs the Attorney General to quickly review and, if appropriate, reschedule any Schedule I drug that has passed late-stage clinical trials for a serious mental health disorder.
What is the real world impact?
•
Provides new hope for veterans and others with severe mental illness
Creates faster pathways for promising but currently restricted psychedelic drugs to be studied and used for treatment. This offers new options for patients who have not found relief with existing therapies.
•
Potentially fast-tracks drugs with unknown long-term effects
Pushes for accelerated approval and access through 'Right to Try,' which might lower the bar for safety and effectiveness. This could expose vulnerable patients to treatments that are not yet fully understood.
When does this start?
This executive order becomes effective on April 18, 2026.